Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
复制标题
DOI：
10.1186/bcr3559
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Alba E
中科院分区：
文献类型：
--
作者：
Ribelles N;Perez-Villa L;Jerez JM;Pajares B;Vicioso L;Jimenez B;de Luque V;Franco L;Gallego E;Marquez A;Alvarez M;Sanchez-Muñoz A;Perez-Rivas L;Alba E
Recurrence risk in breast cancer varies throughout the follow-up time. We examined if these changes are related to the level of expression of the proliferation pathway and intrinsic subtypes. Expression of estrogen and progesterone receptor, Ki-67, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin 5/6 (CK 5/6) was performed on tissue-microarrays constructed from a large and uniformly managed series of early breast cancer patients (N = 1,249). Subtype definitions by four biomarkers were as follows: luminal A (ER + and/or PR+, HER2-, Ki-67 <14), luminal B (ER + and/or PR+, HER2-, Ki-67 ≥14), HER2-enriched (any ER, any PR, HER2+, any Ki-67), triple-negative (ER-, PR-, HER2-, any Ki-67). Subtype definitions by six biomarkers were as follows: luminal A (ER + and/or PR+, HER2-, Ki-67 <14, any CK 5/6, any EGFR), luminal B (ER + and/or PR+, HER2-, Ki-67 ≥14, any CK 5/6, any EGFR), HER2-enriched (ER-, PR-, HER2+, any Ki-67, any CK 5/6, any EGFR), Luminal-HER2 (ER + and/or PR+, HER2+, any Ki-67, any CK 5/6, any EGFR), Basal-like (ER-, PR-, HER2-, any Ki-67, CK5/6+ and/or EGFR+), triple-negative nonbasal (ER-, PR-, HER2-, any Ki-67, CK 5/6-, EGFR-). Each four- or six-marker defined intrinsic subtype was divided in two groups, with Ki-67 <14% or with Ki-67 ≥14%. Recurrence hazard rate function was determined for each intrinsic subtype as a whole and according to Ki-67 value. Luminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady. Luminal B presented most of its relapses during the first five years. HER2-enriched tumors show a peak of recurrence nearly twenty months post-surgery, with a greater risk in Ki-67 ≥14%. However a second peak occurred at 72 months but the risk magnitude was greater in Ki-67 <14%. Triple negative tumors with low proliferation rate display a smooth risk curve, but with Ki-67 ≥14% show sharp peak at nearly 18 months. Each intrinsic subtype has a particular pattern of relapses over time which change depending on the level of activation of the proliferation pathway assessed by Ki-67. These findings could have clinical implications both on adjuvant treatment trial design and on the recommendations concerning the surveillance of patients.
登录
查看更多内容
影响因子：
50.5
作者：
Cancello, G.;Maisonneuve, P.;Colleoni, M.
通讯作者：
Colleoni, M.
影响因子：
45.3
作者：
Hugh, Judith;Hanson, John;Vogel, Charles
通讯作者：
Vogel, Charles
影响因子：
45.3
作者：
Liedtke, Cornelia;Mazouni, Chafika;Pusztai, Lajos
通讯作者：
Pusztai, Lajos
影响因子：
3.8
作者：
Dignam, James J.;Dukic, Vanja;Anderson, Stewart J.;Mamounas, Eleftherios P.;Wickerham, D. Lawrence;Wolmark, Norman
通讯作者：
Wolmark, Norman
影响因子：
6.8
作者：
AKAIKE, H
通讯作者：
AKAIKE, H